We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
Read MoreHide Full Article
Ono Pharmaceutical Co. (OPHLF - Free Report) shares ended the last trading session 10.4% higher at $14.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.2% loss over the past four weeks.
Ono Pharmaceutical’s recent stock gains reflect improving investor confidence around the company’s expanding oncology and specialty medicine portfolio, supported by steady pipeline progress. Growth expectations have been bolstered by multiple regulatory advances for Opdivo (nivolumab), Ono's largest revenue driver, expanded development of Velexbru (tirabrutinib), positive mid-stage data for pipeline candidates ONO-4578 and ONO-2808, and the regulatory filing of Qinlock in Japan. Meanwhile, newer products such as Romvimza and a broader rare disease and cancer portfolio are expected to diversify revenue beyond Opdivo, strengthening the company's long-term growth outlook and supporting investor sentiment.
This company is expected to post quarterly earnings of $0.23 per share in its upcoming report, which represents a year-over-year change of -11.5%. Revenues are expected to be $695.08 million, down 21.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ono Pharmaceutical Co., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OPHLF going forward to see if this recent jump can turn into more strength down the road.
Ono Pharmaceutical Co. is part of the Zacks Medical - Drugs industry. BioCryst Pharmaceuticals (BCRX - Free Report) , another stock in the same industry, closed the last trading session 3.4% higher at $10.17. BCRX has returned 17% in the past month.
For BioCryst, the consensus EPS estimate for the upcoming report has changed +60% over the past month to $0.14. This represents a change of -6.7% from what the company reported a year ago. BioCryst currently has a Zacks Rank of #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
Ono Pharmaceutical Co. (OPHLF - Free Report) shares ended the last trading session 10.4% higher at $14.9. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.2% loss over the past four weeks.
Ono Pharmaceutical’s recent stock gains reflect improving investor confidence around the company’s expanding oncology and specialty medicine portfolio, supported by steady pipeline progress. Growth expectations have been bolstered by multiple regulatory advances for Opdivo (nivolumab), Ono's largest revenue driver, expanded development of Velexbru (tirabrutinib), positive mid-stage data for pipeline candidates ONO-4578 and ONO-2808, and the regulatory filing of Qinlock in Japan. Meanwhile, newer products such as Romvimza and a broader rare disease and cancer portfolio are expected to diversify revenue beyond Opdivo, strengthening the company's long-term growth outlook and supporting investor sentiment.
This company is expected to post quarterly earnings of $0.23 per share in its upcoming report, which represents a year-over-year change of -11.5%. Revenues are expected to be $695.08 million, down 21.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Ono Pharmaceutical Co., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on OPHLF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ono Pharmaceutical Co. is part of the Zacks Medical - Drugs industry. BioCryst Pharmaceuticals (BCRX - Free Report) , another stock in the same industry, closed the last trading session 3.4% higher at $10.17. BCRX has returned 17% in the past month.
For BioCryst, the consensus EPS estimate for the upcoming report has changed +60% over the past month to $0.14. This represents a change of -6.7% from what the company reported a year ago. BioCryst currently has a Zacks Rank of #4 (Sell).